A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This phase 2 study was designed to assess the efficacy and safety of DPX-Survivac plus low
dose cyclophosphamide in up to 24 subjects with recurrent diffuse large B-cell lymphoma
(DLBCL) who are not eligible for transplant. However, with the evolving field of
immunotherapy Immunovaccine has begun to focus on combination therapies, combining
DPX-Survivac treatment with checkpoint inhibitors and other immune modulators. This phase 2
study was therefore terminated with fewer subjects than planned to allow the progress of
other studies, such as NCT03349450.
Phase:
Phase 2
Details
Lead Sponsor:
ImmunoVaccine Technologies, Inc. ImmunoVaccine Technologies, Inc. (IMV Inc.)